JILIN AODONG(SZ:000623) Xin Lang Cai Jing·2026-02-02 03:34Group 1 - Jilin Aodong Pharmaceutical Group Co., Ltd. experienced a decline of 5.09% in stock price, reaching 19.40 CNY per share, with a trading volume of 518 million CNY and a turnover rate of 2.22%, resulting in a total market capitalization of 23.2 billion CNY [1] - The company, established on March 20, 1993, and listed on October 28, 1996, is primarily engaged in the research, development, manufacturing, and sales of traditional Chinese medicine and biochemical drugs, while also expanding into health food, food, breeding, and planting sectors [1] - The revenue composition of Jilin Aodong includes traditional Chinese medicine at 60.90%, wholesale and retail of chain pharmacies at 16.59%, chemical drugs at 12.73%, food at 7.39%, other products at 1.76%, and additional income at 0.62% [1] Group 2 - From the perspective of fund holdings, one fund under China Merchants Asset Management has Jilin Aodong as its second-largest holding, with 17,900 shares, accounting for 2.52% of the fund's net value, resulting in an estimated floating loss of approximately 18,600 CNY today [2] - The fund, China Merchants CSI 500 Index Enhanced Initiation A (023192), was established on January 16, 2025, with a latest scale of 13.4258 million CNY, and has achieved a year-to-date return of 10.94%, ranking 999 out of 5,579 in its category [2] - Over the past year, the fund has generated a return of 48.38%, ranking 1,410 out of 4,285 in its category, and since inception, it has achieved a return of 48.02% [2]